Satsuma Pharmaceuticals, Inc.
STSA · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.07 | 0.04 | -0.03 |
| FCF Yield | -180.37% | -34.30% | -59.19% | -26.16% |
| EV / EBITDA | -0.21 | -2.30 | -1.02 | -3.68 |
| Quality | ||||
| ROIC | -149.15% | -49.96% | -64.46% | -24.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.84 | 0.89 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -15.46% | 5.19% | -57.32% | -308.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 0.29 | 0.72 | 0.67 |
| Interest Coverage | -5,457.46 | -313.90 | -138.08 | -59.92 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |